Medincell Stock Drops Over 2%, Marks a Second Session in the Red
The biotech company from Montpellier continues its decline in early afternoon, contrary to a nearly flat SBF 120. The stock remains stuck at the lower end of the broader index, amid a market environment characterized by renewed tensions in the Middle East and firm Brent prices. Technical analysis shows the stock has returned to its short-term moving average.
A Decline Pushes Medincell to the Bottom of the SBF 120, Contrasting with the CAC 40
Medincell's stock drops 2.3% to €27.20, while the SBF 120 remains stable (+0.05%) and the CAC 40 is stagnant at 8,328.56 points. The stock is among the largest declines in the broader index, extending the slide described in the previous session. Over a week, the stock has lost nearly 7.5%, barely dampening its more than 18% gain over three months and 71% over a year. Meanwhile, the VIX relaxes to 15.99, down 5.4%.
A Stock Returns to its 20-Day Moving Average Following Annual Account Publication
Free · Every morning
Technical market signals, before the opening bell.
Bullish and bearish momentum, analyst changes, stocks to watch — automatically computed from Euronext data.
✓ Before 9 AM every morning✓ Euronext data✓ AI-powered analysis
You're in — subscription confirmed!
Your first edition is on its way. Check your spam folder and add us to your contacts.
An error occurred.
Indicative data. No investment advice. Unsubscribe at any time.
Gratuit · chaque matin
Ne ratez plus rien sur vos actions
La tendance derrière les cours. L'essentiel des valeurs Euronext en quelques minutes.
📈les valeurs en mouvement, sur la durée
🎯les objectifs d'analystes qui évoluent
📰les actualités qui font bouger les cours
tendance · 6 séances
✓ C'est fait, vous êtes inscrit !
Votre première édition arrive bientôt. Pensez à vérifier vos spams.
Une erreur est survenue.
CAC 40 · SBF 120 · données indicatives · aucun conseil en investissement · désinscription à tout moment.
At €27.20, the stock is at its 20-day moving average (€27.11), which it fails to turn into a solid support, while the 50-day moving average (€26.98) and the 200-day moving average (€26.50) remain below the price, marking the potential landing zone in case of further decline. The RSI at 53 is neutral, signaling neither buying pressure nor seller fatigue, reflecting a digestion phase after the volatility of June. The decline follows the shock of the annual results published on June 16, which highlighted a 42% jump in Uzedy royalties to €9.3M but a widened net loss to €31.3M.
During this June 16, 2026 publication, the company also confirmed its target to commercially launch Olanzapine LAI in Q4 2026, identified as the next milestone for the project. The support at €24.08 remains the identified lower boundary by indicators, while the resistance at €29.56, tested unsuccessfully in early July, still caps any rebound attempts.
SectorSanté · Biotechnologies · Vaccins et laboratoires de recherche›Biotechnologie
Free · every morning · before 9am
Never miss a move on your stocks
The trend behind the prices · Euronext
✓ You're in! Check your spam folder.
An error occurred.
Context
Period
Period: 9M 2025
Guidance from the release
We are pleased with the company’s growth and momentum.
Total income €14,1 million; Revenues €11,6 million (+35 %); UZEDY® royalties €4,2 million; Operating result €(6,6) million (improved 13 % year-over-year); Net result €(16 078) thousand; Cash and low-risk financial investments €53,5 million (incl. €49,8 million cash and €3,7 million low-risk investments); Net financial debt €17 629 thousand; NDA for Olanzapine LAI submitted to FDA on December 9, 2025; AbbVie partnership advancing with regulatory package expected in 2026.
Risks mentioned
Foreign exchange risk: weakness of USD vs EUR impacted revenues and generated ~€1 million FX losses
Dependency on partner commercialization (Teva) for UZEDY® royalties and sales forecasts
Regulatory risk: approvals (e.g., Olanzapine LAI) and acceptance for review uncertain
Financial volatility linked to fair value revaluation of EIB BSA warrants (non-cash €6,8 million impact)
Opportunities identified
Olanzapine LAI: NDA submitted and potential launch could be a major growth catalyst
UZEDY®: upward revision of 2025 net sales forecast by Teva (from $160 million to $190-200 million)
AbbVie partnership: first program advancing toward first-in-human trials (regulatory package expected 2026)
Gates Foundation financing: new $3 million envelope to advance mdc-STM malaria program
Expanded geographic approvals (Canada, South Korea) supporting broader commercialization
The information presented in this article is provided for informational purposes only and does not constitute an investment recommendation, an incentive to buy or sell a financial asset, or investment advice. Readers are invited to conduct their own research before making any decision.
Investments in the stock market involve risks, including the risk of capital loss. Past performance of an asset or market is no guarantee of future results. Any investment decision should be made taking into account your personal financial situation, objectives and risk tolerance.
